{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
vasopressin
to a specific field?
Status:
Investigational
Source:
NCT00358878: Phase 3 Interventional Completed Ascites
(2006)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Sanofi-Synthélabo has developed satavaptan (previously known as SR121463) as a non-peptidic vasopressin V2 receptor antagonist for the potential treatment for cardiovascular indications such as congestive heart failure (CHF) and hypertension. The drug reached phase II for these indications before the studies were discontinued. Satavaptan was also studied for the potential treatment of glaucoma. In addition, this drug was involved in phase III clinical trials in patients with ascites due to cirrhosis of the liver and in in patients with dilutional hyponatremia. However, the further development of the satavaptan was discontinued in 2009.
Status:
Investigational
Source:
NCT01606384: Phase 2 Interventional Completed Major Depressive Disorder
(2006)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Nelivaptan is a selective, orally active, non-peptide vasopressin receptor antagonist selective for the V1B subtype. It showed promise in preclinical animal models and advanced to phase II clinical trials for the treatment of anxiety and depression; however, in 2008, Sanofi-Aventis announced that further development of this drug had been halted.
Status:
Investigational
Source:
NCT02507284: Phase 2 Interventional Completed Irritable Mood
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Class (Stereo):
CHEMICAL (ABSOLUTE)
Ataprost (also known as ONO-41483; OP-41483), an epoprostenol agonist, participated in phase II clinical trials in Japan for the treatment patients with heart failure and myocardial ischemia. However, these trials were discontinued.
Status:
Other
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
WAY 267464 dihydrochloride is a potent and selective agonist at the oxytocin receptor (OTR). WAY 267464 has been shown to cross the blood-brain-barrier to a significantly greater extent than exogenously applied oxytocin. WAY 267464 dose-dependently reduced anxiety on the four-plate test and prevented the deficits in prepulse inhibition induced by MK-801 or amphetamine. The ability of WAY 267464 to function as a V1AR antagonist may limit its potential therapeutic use in humans, as it would conceivably prevent the improvements in social behavior and social cognition that may be assumed to arise from a primary OTR agonist action.
Status:
Other
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
TC OT 39 was developed as potent non-peptide oxytocin receptor partial agonist and V2 vasopressin receptor agonist. Also was a V1a vasopressin receptor antagonist.
![Structure of 2?-(7,7-Dimethylspiro[furo[3,4-b]pyridine-5(7H),4?-piperidin]-1?-yl)-1,3-dihydrospiro[2H-indene-2,5?(4?H)-oxazol]-4?-one](/img/fb794b1e-de26-494e-90f0-ca37a75c0df8.svg?size=200&context=yjdcciturc)
